OpenAI president Greg Brockman told WSJ Tech in Napa on Wednesday, in an interview with Wall Street Journal reporter Keach Hagey, that AI will deliver significant progress on biology, health and disease within the next 12 to 18 months. He acknowledged that promising cures has become a trope in the industry, but said this round of results would be different.

He also raised the prospect of 'death becoming a choice,' without giving it a timeline. The claim sits on real product ground: OpenAI's GPT-Rosalind, a reasoning model for biology and drug discovery, came out of research preview in September with partners including Amgen, Moderna, Thermo Fisher Scientific and the Allen Institute — though at its own launch OpenAI noted that US drugs typically take 10 to 15 years from target discovery to approval.

Read the 18-month prediction as a forecast about research speed, not about treatments reaching patients: measurable lab progress on that schedule is plausible, approved cures would be unprecedented, and AI executives have been promising breakthroughs within a year or two since ChatGPT launched. Matthew Berman's November 6 briefing flagged the remarks as OpenAI's health forecast.